Novartis has reported positive data from a real-world comparison study of its Jakavi (ruxolitinib) drug conducted to treat patients with polycythemia vera (PV), a rare incurable blood cancer.
Jakavi is an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases. The study showed a significant decline in the risk of thrombosis (blood clots) and death in PV patients who are resistant or intolerant to hydroxyurea, when compared to those treated using the ‘best available therapy’.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
These results are based on comparing the Phase III RESPONSE Jakavi clinical trial participants and the real-world Spanish GEMFINI patient registry.
A separate efficacy analysis indicated reductions in spleen size reductions for those with lower-risk myelofibrosis (MF) patients treated with Jakavi, while another analysis detected factors related to better spleen response.
Novartis Oncology Global Drug Development head Samit Hirawat said: “With limited treatment options, patients with myeloproliferative neoplasms often struggle to keep their disease under control.
“The research conducted by Novartis teams and our physician partners in both PV and MF is helping to clarify how Jakavi can help relieve disease burden for patients.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataJakavi secured the European Commission approval to treat adult PV patients who are resistant to or intolerant of hydroxyurea, and disease-related splenomegaly or symptoms in those with primary MF.
The drug currently has been approvaled in 101 countries for MF patients and in more than 75 countries to treat patients suffering from PV, with additional regulatory submissions underway in other markets.
